Article
Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication.
Antiviral therapy - 1 Jan 2008
Lutgehetmann Marc, Volzt Tassilo, Quaas Alexander, Zankel Myrga, Fischer Conrad, Dandri Maura, Petersen Joerg
Abstract excerpt
BACKGROUND: We previously reported that 48 weeks of combination therapy with pegylated interferon-alpha2b (PEG-IFN-alpha2b) and adefovir dipivoxil (ADV) in patients with chronic hepatitis B led to marked decreases of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) (-2.4 log10 copies/ml). Combination therapy was followed by 96 weeks of ADV monotherapy. METHODS: Here, we report on the final outcome...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
